Thymalin and Thymogen in gestational anemia: historical human comparisons
T. E. Belokrinitskaya · 1995 · Doctoral dissertation author’s abstract. Irkutsk, 1995; work conducted at Chita Medical Academy
Historical human pregnancy exposure · Pregnancy and offspring evidence review ↗
Reported findings and study design
Reported findings
In the 24-woman prevention subgroup, anemia by week 36 was reported in 2/12 Thymalin-treated women versus 6/12 controls. The larger treatment program described fewer obstetric complications, but did not isolate each peptide or establish randomized effects.
Historical clinical and experimental dissertation program; women aged 17–40. Iron/vitamins as background treatment; separate heparin group; 100-woman longitudinal biomarker subgroup and HLA-selected 24-woman prevention comparison. These overlapping subsets must not be added to the program total.
Dose, route and schedule
Adjunct Thymalin or Thymogen with iron and vitamins. Prevention subgroup: five-day Thymalin courses reported at weeks 20 and 28, monitoring through week 36. Recommendation section gives different timing (16 and 24 weeks). Historical methods are not current obstetric guidance.
Protocol source ↗ · Medical-Diss transcription of the author’s abstract; methods and clinical/prevention results checked; full original thesis not recovered
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Prevention subgroup: anemia | 2/12 with Thymalin versus 6/12 controls | HLA-selected risk subgroup; control anemia included four mild and two moderate cases · Gestation week 36 · No randomized allocation, confidence interval or inferential p-value established |
| Treatment-program complications | Authors report 1.72-fold lower frequency of selected delivery complications | Combined immunomodulator regimens versus conventional care; no compound-specific raw event table verified · Narrative p<0.05; not a verified independent peptide risk reduction |
| Time to clinical improvement | Reported 4.2 ± 0.6 days earlier with immunocorrective care | Compared with heparin or conventional treatment; bundled clinical/laboratory/ultrasound measures |
| Animal arm: separate evidence | Pregnant-rat erythrocyte and reticulocyte changes also reported | Animal results are not patient outcomes; erythrocyte-derived experimental peptides are not Thymalin or Thymogen |
Historical nonrandomized multimodal care; the study does not establish efficacy or safety of either peptide in current pregnancy care. Third-party author-abstract transcription, not an authenticated 313-page thesis with 49 original tables. Treatment-arm sizes for Thymalin and Thymogen individually are not supplied. The 12/12 prevention comparison is small and selected. Claims of 83.3% prevention lack a randomized counterfactual and must not be advertised as treatment efficacy. Narrative prevention timing is weeks 20 and 28; recommendation section says weeks 16 and 24. The schedules conflict. No comprehensive congenital-anomaly or long-term child-safety assessment is available.
Source for the extracted data ↗ · Checked 2026-11-08
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- Historical nonrandomized multimodal care; the study does not establish efficacy or safety of either peptide in current pregnancy care.
- Third-party author-abstract transcription, not an authenticated 313-page thesis with 49 original tables. Treatment-arm sizes for Thymalin and Thymogen individually are not supplied.
- The 12/12 prevention comparison is small and selected. Claims of 83.3% prevention lack a randomized counterfactual and must not be advertised as treatment efficacy.
- Narrative prevention timing is weeks 20 and 28; recommendation section says weeks 16 and 24. The schedules conflict. No comprehensive congenital-anomaly or long-term child-safety assessment is available.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Dissertation author-abstract transcription
Review depth: Medical-Diss transcription of the author’s abstract; methods and clinical/prevention results checked; full original thesis not recovered
Related-report group: chita-gestational-anemia-1991-1995. Reports in this group are not assumed to be independent trials.
Source access and review scope
Medical-Diss transcription of the author’s abstract; methods and clinical/prevention results checked; full original thesis not recovered
Recorded source-check date: 2026-11-08. This date does not imply a completed systematic review.
Source type: Dissertation author-abstract transcription
Citation and original source
Original source: T. E. Belokrinitskaya. Thymalin and Thymogen in gestational anemia: historical human comparisons Doctoral dissertation author’s abstract. Irkutsk, 1995; work conducted at Chita Medical Academy 1995.
Molekul research summary: https://molekul.io/research/pregnancy-thymalin-thymogen-anemia-1995. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entryRelated compound profiles
Thymalin
Thymus-derived peptide mixture with historical Russian studies in autoimmune cytopenias and thyroiditis, alongside other treatments. It is distinct from synthetic Thymogen and Thymodepressin.
Thymogen
EW is discussed in the thymus-derived research program. Thymalin extract outcomes cannot be assigned to this defined peptide.